Re:Cognition Health: Dustin Reibe

Dustin Reibe

Re:Cognition Health has appointed Dustin Reibe as director, clinical services, responsible for the leadership and development of its private patient and medicolegal business and developing and expanding its neurological and neuro-psychiatric specialist services for acquired, traumatic, developmental and neurodegenerative conditions affecting the brain and mind.

Reibe will be expanding Re:Cognition’s existing services for all ages, from young children with autism to the older population with Alzheimer’s. In addition, he will be leading the introduction of the company’s new medicinal cannabis and Long Covid clinics.

Reibe said: “Re:Cognition Health’s vision to change the future of brain and mind health is inspirational and I am thrilled be in a unique position, at the forefront of innovation in brain and mind services, for the future. Cognitive health is an increasingly significant health priority, due to the UK’s ageing demographic and individual lifestyle choice, for a healthy brain and mind, at all ages. My goal is to expand Re:Cognition’s footprint within the UK and position the company to meet future demands. I am looking forward to working with incredible clinicians, partners and the private medical insurers.”

Dr Emer MacSweeney, founder and chief executive of Re:Cognition Health, added: “We are delighted Dustin has joined our energetic and forward thinking team. This is an extremely exciting time, worldwide, for new biomarkers and medications for diseases affecting the brain and mind. The rate of change and process in this challenging arena of healthcare has never been more rapid. It is a great time for the company to welcome an individual with Dustin’s commercial healthcare knowledge, operational skills and entrepreneurial experience.

Carter Schwartz advised on this appointment.

Join our mailing list

Stay up to date with all our events, awards and publications.

Information you provide us with will be kept private at all times, and will be used for communication and research purpose only.